How to safely conduct medicinal marijuana therapy? Review article
Article Sidebar
Published:
Jun 30, 2024
Keywords:
medical marijuana, therapy, side effects
Main Article Content
Abstract
This paper is discussing a Canadian study published 3 years ago in the “European Journal of Internal Medicine”. It describes the principles of conducting and monitoring medical marijuana therapy. Information on adverse reactions, dosage methods, selection of active substances and modification of treatment has been also presented.
Article Details
How to Cite
Sapilak, B. J. (2024). How to safely conduct medicinal marijuana therapy?. Medycyna Faktow (J EBM), 17(2(63), 174-178. https://doi.org/10.24292/01.MF.0224.01
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. MacCallum CA, Lo LA, Boivin M. “Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations. Eur J Intern Med. 2021; 89: 10-8. https://doi.org/10.1016/j.ejim.2021.05.002.
2. Mechoulam R, Peters M, Murillo-Rodriguez E et al. Cannabidiol-recent advances. Chem Biodivers. 2007; 4(8): 1678-92.
3. Pisanti S, Malfitano AM, Ciaglia E et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017; 175: 133-50.
4. Devinsky O, Marsh E, Friedman D et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016; 15(3): 270-8.
5. Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017; 72: 310-24.
6. Bergamaschi MM, Queiroz RH, Chagas MH et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011; 36: 1219-26.
7. MacCallum CA, Lo LA, Betts F et al. Chapter 31: product safety and quality control. Cannabinoids and Pain. Springer US, 2021. https://doi.org/10.1007/978- 3-030-69186-8_31.
8. Abuhasira R, Schleider LB-L, Mechoulam R et al Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Internal Med. 2018; 49: 44-50. https://doi.org/10.1016/j.ejim.2018.01.019.
9. Rein JL. The nephrologistis guide to cannabis and cannabinoids. Curr Opin Nephrol. Hypertens 2020; 29(2): 248-57. https://doi.org/10.1097/MNH.0000000000000590.
10. Layden JE, Ghinai I, Pray I et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin – preliminary report. N Engl J Med. 2020; 382(10): 903-16. https://doi.org/10.1056/NEJMoa1911614.
11. Eadie L, Lo LA, Christiansen A et al. Duration of neurocognitive impairment with medical cannabis use: a scoping review. Front Psychiatry 2021; Mar 12. https://doi.org/10.3389/fpsyt.2021.638962.
12. Atsmon J , Heffetz D, Deutsch L et al. Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. Clinical Pharmacology in Drug Development. 2017; 00(0): 1-8. https://doi.org/10.1002/cpdd.408.
2. Mechoulam R, Peters M, Murillo-Rodriguez E et al. Cannabidiol-recent advances. Chem Biodivers. 2007; 4(8): 1678-92.
3. Pisanti S, Malfitano AM, Ciaglia E et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017; 175: 133-50.
4. Devinsky O, Marsh E, Friedman D et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016; 15(3): 270-8.
5. Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017; 72: 310-24.
6. Bergamaschi MM, Queiroz RH, Chagas MH et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011; 36: 1219-26.
7. MacCallum CA, Lo LA, Betts F et al. Chapter 31: product safety and quality control. Cannabinoids and Pain. Springer US, 2021. https://doi.org/10.1007/978- 3-030-69186-8_31.
8. Abuhasira R, Schleider LB-L, Mechoulam R et al Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Internal Med. 2018; 49: 44-50. https://doi.org/10.1016/j.ejim.2018.01.019.
9. Rein JL. The nephrologistis guide to cannabis and cannabinoids. Curr Opin Nephrol. Hypertens 2020; 29(2): 248-57. https://doi.org/10.1097/MNH.0000000000000590.
10. Layden JE, Ghinai I, Pray I et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin – preliminary report. N Engl J Med. 2020; 382(10): 903-16. https://doi.org/10.1056/NEJMoa1911614.
11. Eadie L, Lo LA, Christiansen A et al. Duration of neurocognitive impairment with medical cannabis use: a scoping review. Front Psychiatry 2021; Mar 12. https://doi.org/10.3389/fpsyt.2021.638962.
12. Atsmon J , Heffetz D, Deutsch L et al. Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. Clinical Pharmacology in Drug Development. 2017; 00(0): 1-8. https://doi.org/10.1002/cpdd.408.